跳至主要内容
临床试验/ACTRN12610000437066
ACTRN12610000437066已完成4 期

The effect of Pantoprazole in comparison to placebo on phosphate control in haemodialysis patients taking phosphate binders.

King Saud University0 个研究点目标入组 70 人开始时间: 2010年5月28日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1- Currently receiving haemodialysis treatment for >1 month at The Queen Elizabeth Hospital, The Royal Adelaide Hospital, or affiliated satellite dialysis units (stable regimen during study period).
  • 2- Patient receiving single agent phosphate binders (stable regimen during study period).
  • This include: Calcium Carbonate, Lanthanum Carbonate, Sevelamer hydrochloride, Aluminum Hydroxide.

排除标准

  • 1- < 18 years of age.
  • 2- Patients unable to give informed consent.
  • 3- Patients enrolled in other investigational drug treatments
  • 4- Patients deemed unable to comply with treatment regime.
  • 5- Home dialysis patients.
  • 6- Peritoneal dialysis patients.
  • 7- Severe indication for acid suppression where withdrawal of acid suppression therapy is deemed unacceptable by the caring physician. (e.g.)
  • a- Major active peptic ulcer diseases
  • b- Major recent gastrointestinal bleeding
  • C- Major Gastro-Oesophageal Reflux Disease (GORD)
  • d- Major gastro-intestinal problems on 7-point Global Overall Symptom (GOS28) scale.

研究者

相似试验

Effect of acid suppression on the effectiveness of... | 临床试验